UB Paderborn / Katalog / Suche / in CDI

Clinical guideline SEOM: hepatocellular carcinoma

Clinical & translational oncology, 2015-12, Vol.17 (12), p.988-995

2015

Volltextzugriff (PDF)

Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS)

Annals of oncology, 2017-12, Vol.28 (12), p.2994-2999

2017

Volltextzugriff (PDF)

SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016)

Clinical & translational oncology, 2016-12, Vol.18 (12), p.1179-1186

2016

Volltextzugriff (PDF)

Clinical guideline SEOM: hepatocellular carcinoma

Clinical & translational oncology, 2015-12, Vol.17 (12), p.988-995

2015

Volltextzugriff (PDF)

2250 Phase II trial of neoadjuvant gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy in resectable pancreatic adenocarcinoma. A GEMCAD 10–03 trial

European journal of cancer (1990), 2015-09, Vol.51, p.S416-S416

2015

Volltextzugriff (PDF)

P-182 Multicenter real-world data of treatment with NALIRI plus 5FU/LV in advanced Spanish pancreatic cancer

Annals of oncology, 2023-06, Vol.34, p.S80-S81

2023

Volltextzugriff (PDF)

1114P Encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma, real-world evidence in Spain (GEM 2002 - BECARE)

Annals of oncology, 2023-10, Vol.34, p.S671-S672

2023

Volltextzugriff (PDF)

1932P First in human trial of CEB-01 for retroperitoneal soft tissue sarcoma

Annals of oncology, 2023-10, Vol.34, p.S1038-S1038

2023

Volltextzugriff (PDF)

P.16 Social support of elderly lung cancer patients

Critical reviews in oncology/hematology, 2007-11, Vol.64, p.S40-S40

2007

Volltextzugriff (PDF)

An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib

Clinical & translational oncology, 2018-03, Vol.20 (3), p.322-329

2018

Volltextzugriff (PDF)

PO-1557 RT after Encorafenib and Binimetinib on BRAF mutated melanoma brain metastases. GEM1802-Phase II

Radiotherapy and oncology, 2023-05, Vol.182, p.S1264-S1264

2023

Volltextzugriff (PDF)

837P Real-world evidence of encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma in Spain (GEM 2002 - BECARE)

Annals of oncology, 2022-09, Vol.33, p.S932

2022

Volltextzugriff (PDF)

2288 Validation of the Memorial Sloan Kettering Cancer Center (MSKCC) nomogram after surgery for localized pancreatic adenocarcinoma: Long-term results from a Spanish pancreatic cancer surgery reference centre

European journal of cancer (1990), 2015-09, Vol.51, p.S428-S428

2015

Volltextzugriff (PDF)

2326 An internally validated new clinical prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib

European journal of cancer (1990), 2015-09, Vol.51, p.S441-S441

2015

Volltextzugriff (PDF)

2325 A study of the representativity of the NCIC, PRODIGE and MPACT phase III trials of gemcitabine-erlotinib, FOLFIRINOX and gemcitabine-nab-paclitaxel in patients with advanced pancreatic cancer treated in a real-life setting

European journal of cancer (1990), 2015-09, Vol.51, p.S441-S441

2015

Volltextzugriff (PDF)

2134 Comparative analysis of the Kohne, GERCOR and GEMCAD prognostic models in metastatic colorectal cancer (mCRC) patients treated with first-line bevacizumab-based combination chemotherapy

European journal of cancer (1990), 2015-09, Vol.51, p.S376-S377

2015

Volltextzugriff (PDF)

Carcinoma of unknown primary site: development in a single institution of a prognostic model based on clinical and serum variables

Clinical & translational oncology, 2007-07, Vol.9 (7), p.452-458

2007

Volltextzugriff (PDF)

P-190Update of metastatic colorectal cancer metastases resection after FOLFIRI-aflibercept in oxaliplatin-refractory patients

Annals of oncology, 2019-07, Vol.30 (Supplement_4)

2019

Volltextzugriff (PDF)

A phase I and randomized phase II trial to evaluate the efficacy and safety of nab-paclitaxel (nab-P) in combination with gemcitabine (G) for the treatment of patients with ECOG 2 advanced pancreatic cancer (PDAC)

Annals of oncology, 2017-09, Vol.28, p.v212-v212

2017

Volltextzugriff (PDF)

Identification Of Actionable Genetic Targets In Primary Cardiac Sarcomas

OncoTargets and therapy, 2019-11, Vol.12, p.9265-9275

2019

Volltextzugriff (PDF)

Reproductive risk factors of breast cancer in elderly population. A single centre study

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.21187-21187

2007

Volltextzugriff (PDF)

Neutrophil-to-lymphocyte ratio as a biomarker for prognosis in localized colorectal carcinoma

Annals of oncology, 2016-10, Vol.27, p.vi201-vi201

2016

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Clinical guideline SEOM: hepatocellular carcinoma

Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS)

Update of metastatic colorectal cancer metastases resection after FOLFIRI-aflibercept in oxaliplatin-refractory patients

SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016)

Clinical guideline SEOM: hepatocellular carcinoma

2250 Phase II trial of neoadjuvant gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy in resectable pancreatic adenocarcinoma. A GEMCAD 10–03 trial

P-182 Multicenter real-world data of treatment with NALIRI plus 5FU/LV in advanced Spanish pancreatic cancer

1114P Encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma, real-world evidence in Spain (GEM 2002 - BECARE)

1932P First in human trial of CEB-01 for retroperitoneal soft tissue sarcoma

P.16 Social support of elderly lung cancer patients

An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib

PO-1557 RT after Encorafenib and Binimetinib on BRAF mutated melanoma brain metastases. GEM1802-Phase II

837P Real-world evidence of encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma in Spain (GEM 2002 - BECARE)

1038MO Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial

2288 Validation of the Memorial Sloan Kettering Cancer Center (MSKCC) nomogram after surgery for localized pancreatic adenocarcinoma: Long-term results from a Spanish pancreatic cancer surgery reference centre

2326 An internally validated new clinical prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib

2325 A study of the representativity of the NCIC, PRODIGE and MPACT phase III trials of gemcitabine-erlotinib, FOLFIRINOX and gemcitabine-nab-paclitaxel in patients with advanced pancreatic cancer treated in a real-life setting

2134 Comparative analysis of the Kohne, GERCOR and GEMCAD prognostic models in metastatic colorectal cancer (mCRC) patients treated with first-line bevacizumab-based combination chemotherapy

Carcinoma of unknown primary site: development in a single institution of a prognostic model based on clinical and serum variables

P-190Update of metastatic colorectal cancer metastases resection after FOLFIRI-aflibercept in oxaliplatin-refractory patients

A phase I and randomized phase II trial to evaluate the efficacy and safety of nab-paclitaxel (nab-P) in combination with gemcitabine (G) for the treatment of patients with ECOG 2 advanced pancreatic cancer (PDAC)

Identification Of Actionable Genetic Targets In Primary Cardiac Sarcomas

Clinicopathologic features and long-term follow-up of metastatic gastrointestinal stromal tumor (GIST) patients (pts) with durable response (≥ 5 years) to frontline imatinib (IM): A case-control study from GEIS

Reproductive risk factors of breast cancer in elderly population. A single centre study

Neutrophil-to-lymphocyte ratio as a biomarker for prognosis in localized colorectal carcinoma

Suchergebnisse filtern